GlaxoSmithKline (GB:GSK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GSK’s latest trial results reveal that Blenrep, in combination with other drugs, significantly reduces the risk of death in multiple myeloma patients by 42% compared to the standard treatment. These findings highlight Blenrep’s potential to become a new standard of care, with regulatory reviews underway in major markets. Investors might find GSK’s advancements in this treatment promising for the company’s growth and stock performance.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
